---
schema_version: "secwatch.filing_event.v1"
accession: "0001534969-22-000033"
form_type: "8-K"
ticker: "SERA"
cik: "0001534969"
company_name: "SERA PROGNOSTICS, INC."
filed_at: "2022-03-29T23:59:59+00:00"
generated_at: "2026-06-26T14:43:44.571533+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sera Prognostics Q4 2021 revenue $26k, net loss $12.5M; losses widen as commercial ops scale

## Summary
- Q4 2021 revenue rose to $26k from $6k YoY; net loss of $12.5M vs $5.4M.
- Full-year 2021 revenue $82k, total operating expenses $35.5M (up from $18M).
- Cash and securities totaled $139.9M as of Dec 31, 2021.
- CMS set Medicare payment rate of $750 for PreTRM test; added to NASDAQ Biotechnology Index.
- R&D spend increased to $3.1M in Q4; SG&A jumped to $9.5M on higher headcount and public company costs.

## SEC filing metadata
- accession: 0001534969-22-000033
- form_type: 8-K
- ticker: SERA
- cik: 0001534969
- company_name: SERA PROGNOSTICS, INC.
- filed_at: 2022-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000033/0001534969-22-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000033/sera-20220329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534969-22-000033
- JSON: https://secwatch.observer/filing/0001534969-22-000033.json
- Plain text: https://secwatch.observer/filing/0001534969-22-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.